Beyond guideline‑directed medical therapy for heart failure with ejection fraction less than 40%, what additional management considerations are important, such as implantation of an automatic implantable cardioverter‑defibrillator and anticoagulation?

Beyond GDMT for HFrEF: ICD and Anticoagulation Considerations

For patients with HFrEF (LVEF ≤35%) on optimal GDMT for ≥3 months (or ≥40 days post-MI), ICD implantation is recommended for primary prevention of sudden cardiac death if they have NYHA class II-III symptoms, acceptable non-cardiac health, and life expectancy >1 year with good functional capacity. 1, 2

ICD Therapy: Primary Prevention

Class I Indications (Strongly Recommended)

Ischemic Cardiomyopathy:

• LVEF ≤30-40%, ≥40 days post-MI
• NYHA class II or III on optimal GDMT
• Life expectancy >1 year with good functional status 3

Non-ischemic Cardiomyopathy:

• LVEF ≤30-35%
• NYHA class II or III on optimal GDMT
• Life expectancy >1 year with good functional status 3, 4

Critical Timing Consideration

You must wait at least 3 months on contemporary GDMT before ICD implantation because modern quadruple therapy (ARNI/ACEi, beta-blocker, MRA, SGLT2i) produces substantial LVEF improvement within weeks to months. 5, 6 Recent evidence shows that contemporary GDMT reduces sudden cardiac death risk significantly, potentially altering the benefit-risk ratio of prophylactic ICDs, particularly in non-ischemic cardiomyopathy. 6

When NOT to Implant ICD (Class III)

Do not implant if:

• Advanced frailty or comorbidities limiting survival to <1 year 1, 2
• Frequent HF hospitalizations suggesting high risk of non-sudden death 2
• NYHA class IV refractory symptoms (unless transplant candidate) 7
• Severe renal dysfunction or systemic malignancy 2

The evidence is clear that ICDs provide uncertain benefit when non-sudden death risk exceeds sudden death risk. 2

Cardiac Resynchronization Therapy (CRT)

Class I Indications (CRT-D Preferred)

NYHA Class II-III with:

• LVEF ≤35%
• Sinus rhythm
• QRS ≥150 ms with LBBB pattern
• On optimal GDMT 1, 2

NYHA Class III-Ambulatory IV:

• Same criteria as above
• CRT-pacing (without ICD) acceptable if ICD unlikely to provide meaningful survival benefit based on comorbidities 1

Class IIa Indications

• Atrial fibrillation patients requiring ventricular pacing with AV nodal ablation or rate control achieving near 100% ventricular pacing 2
• Patients undergoing new/replacement device with anticipated >40% ventricular pacing 2

Class IIb (May Consider)

• NYHA class I: LVEF ≤30%, ischemic etiology, LBBB with QRS ≥150 ms 2
• Non-LBBB patterns with QRS ≥150 ms in NYHA class II 2

Do NOT Use CRT (Class III)

• NYHA class I-II with non-LBBB pattern and QRS <150 ms 1, 2
• Life expectancy <1 year due to comorbidities 1

Anticoagulation in HFrEF

The Evidence Gap

Anticoagulation is NOT routinely recommended in HFrEF patients in sinus rhythm. The guidelines do not support prophylactic anticoagulation based solely on low LVEF or HF diagnosis. 8

When Anticoagulation IS Indicated

Atrial Fibrillation:

• Primary indication for anticoagulation in HF patients 8
• Direct oral anticoagulants (DOACs/NOACs) are preferred over warfarin 8
• Use CHA₂DS₂-VASc score for risk stratification (HF adds 1 point)

Other Standard Indications:

• Left ventricular thrombus
• Recent MI with anterior wall akinesis
• Mechanical heart valves
• Venous thromboembolism

Common Pitfall

Do not anticoagulate HFrEF patients in sinus rhythm without another clear indication. Despite theoretical concerns about intracardiac thrombus formation with severe LV dysfunction, randomized trials have not demonstrated benefit from routine anticoagulation in this population.

Practical Implementation Algorithm

Step 1: Optimize all 4 pillars of GDMT (ARNI/ACEi, beta-blocker, MRA, SGLT2i) rapidly—target "4 drugs in 4 weeks" 9

Step 2: Reassess LVEF after 3 months of optimal GDMT 5, 6

Step 3: If LVEF remains ≤35%:

• Assess NYHA class
• Obtain 12-lead ECG for QRS duration/morphology
• Evaluate comorbidities and life expectancy
• Check rhythm (sinus vs. atrial fibrillation)

Step 4: Apply device criteria:

• NYHA II-III + ischemic/non-ischemic → ICD
• Add CRT if QRS ≥150 ms with LBBB
• Consider CRT-pacing alone if ICD benefit uncertain due to comorbidities

Step 5: Anticoagulation only if atrial fibrillation or other standard indication present

Key Caveats

The benefit of ICD in non-ischemic cardiomyopathy with LVEF 31-35% is less robust than in those with LVEF ≤30%. 4 Consider electrophysiology study in this borderline group to identify higher-risk patients. 4

For patients with atrial fibrillation and HFrEF, catheter ablation may improve LVEF sufficiently to eliminate ICD indication—72% of patients achieve LVEF >35% within 6 months post-ablation, particularly in non-ischemic etiology. 10